Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $13.3 million.

  • Adma Biologics' Cash from Operations fell 4688.75% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 2449.65%. This contributed to the annual value of $118.7 million for FY2024, which is 124854.55% up from last year.
  • As of Q3 2025, Adma Biologics' Cash from Operations stood at $13.3 million, which was down 4688.75% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Cash from Operations peaked at $50.2 million during Q4 2024, and registered a low of -$33.5 million during Q4 2021.
  • For the 5-year period, Adma Biologics' Cash from Operations averaged around -$1.6 million, with its median value being -$7.4 million (2022).
  • As far as peak fluctuations go, Adma Biologics' Cash from Operations soared by 85335.86% in 2024, and later tumbled by 78706.04% in 2025.
  • Over the past 5 years, Adma Biologics' Cash from Operations (Quarter) stood at -$33.5 million in 2021, then surged by 77.95% to -$7.4 million in 2022, then skyrocketed by 338.47% to $17.6 million in 2023, then soared by 185.37% to $50.2 million in 2024, then plummeted by 73.53% to $13.3 million in 2025.
  • Its Cash from Operations was $13.3 million in Q3 2025, compared to $21.1 million in Q2 2025 and -$19.7 million in Q1 2025.